|
In patients with reduced renal function, the plasma half-life may be prolonged up to 5.2 hours depending on the degree of the renal dysfunction. In patients with complete absence of renal function, the plasma half-life of cefprozil has been shown to be as long as 5.9 hours. The half-life is shortened during hemodialysis. Excretion pathways in patients with markedly impaired renal function have not been determined. (See PRE-CAUTIONS and DOSAGE AND ADMINISTRATION.) In patients with impaired hepatic function, the half-life increases to approximately 2 hours. The magnitude of the changes does not warrant a dosage adjustment for patients with impaired hepatic function. Healthy geriatric volunteers ( 65 years old) who received a single 1-g dose of cefprozil had 35%-60% higher AUC and 40% lower renal clearance values compared with healthy adult volunteers 20-40 years of age. The average AUC in young and elderly female subjects was approximately 15-20% higher than in young and elderly male subjects. The magnitude of these age-and gender-related changes in the pharmacokinetics of cefprozil is not sufficient to necessitate dosage adjustments. Text Continues Below
Adequate data on CSF levels of cefprozil are not available. Comparable pharmacokinetic parameters of cefprozil are observed between pediatric patients (6 monthsÐ 12 years) and adults following oral administration of selected matched doses. The maximum concentrations are achieved at 1Ð 2 hours after dosing. The plasma elimination half-life is approximately 1.5 hours. In general, the observed plasma concentrations of cefprozil in pediatric patients at the 7.5, 15, and 30 mg/ kg doses are similar to those observed within the same time frame in normal adult subjects at the 250, 500 and 1000 mg doses, respectively. The comparative plasma concentra-tions of cefprozil in pediatric patients and adult subjects at the equivalent dose level are presented in the table below. Page: << Prev | 1 | 2 | 3 | 4 | 5 | Next >>
|
.gif)
